BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31954536)

  • 1. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
    Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
    Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
    Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
    Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study.
    Li Y; Ren H; Wang J
    BMC Cancer; 2019 Jul; 19(1):697. PubMed ID: 31307426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine leiomyosarcoma: an updated series.
    Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
    Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
    Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
    Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
    Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
    Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Cosio S; Tisi G; Lissoni A; Ferrero AM; Cristofani R
    Eur J Gynaecol Oncol; 2002; 23(4):295-9. PubMed ID: 12214727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
    Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
    Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study.
    Costales AB; Radeva M; Ricci S
    J Gynecol Oncol; 2020 May; 31(3):e21. PubMed ID: 32266798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
    Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
    Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
    Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.
    Singh N; Al-Ruwaisan M; Batra A; Itani D; Ghatage P
    J Obstet Gynaecol Can; 2020 Dec; 42(12):1483-1488. PubMed ID: 32900677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.